Navigation Links
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
Date:7/31/2008

AURORA, Colo., July 31 /PRNewswire/ -- Sierra Neuropharmaceuticals, Inc., a formulator of pharmaceuticals for direct-to-the-brain treatment of neurological diseases, announced a $21.5-million venture capital Series A financing. Co-leads in the funding were HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners. Other investors include High Country Venture and GC&H Investments LLC.

Sierra uses a proprietary drug development process that makes use of standard implantable pumps placed surgically under the skin which deliver drugs directly to the fluid around the brain via a catheter. The approach aims to help patients suffering from severe epilepsy, depression, schizophrenia and other neurological diseases who, until now, have had to treat their conditions by taking drugs orally. "Many current oral therapies are limited in their use due to severe side effects and possible toxicities," says Daniel Abrams, M.D., Sierra's founder, Chief Scientific Officer, and Acting CEO. "For patients, this means they may be denied access to medicines that could otherwise be of great benefit. Even for those drugs that can safely be taken orally, patients often have difficulty maintaining a proper pill regimen and may take only 50-80% of their required dosage. By reformulating existing pharmaceuticals and delivering them via an implanted device, better treatment and new options can be made available to patients."

It is estimated that more than 10 million people in the United States and Europe suffer from severe neurological diseases not adequately treated by current oral medications and would benefit from a new approach. "We think Sierra's new approach offers a broad new pathway for treating neurological diseases," he says, "and an opportunity to enhance patient lives."

To further develop therapies and win FDA approval, Abrams says Sierra will work closely with both pump manufacturers and pharmaceutical companies. The latter, he says, could col
'/>"/>

SOURCE Sierra Neuropharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NuVasive Completes Acquisition of Osteocel Biologics Business
2. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
3. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
4. Accuri Cytometers Completes $13 Million Series C Financing
5. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
6. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
7. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
8. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
9. Boston Scientific Completes Acquisition of CryoCor
10. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
11. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... YORK , August 3, 2015 ... Market Study on 3D Cell Culture: Asia ... by Persistence Market Research, the global 3D cell culture market was ... expected to expand at a CAGR of 29.1% to ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm ... quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC International ... “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... assay effectively identifies melanoma, LA JOLLA, Calif., ... diagnostics for the early detection of,melanoma and other ... Cancer Research on its non-invasive assay that distinguishes ... Genomic Assay for,the Detection of Melanoma in Suspicious ...
... CEDAR KNOLLS, N.J., April 15 Emisphere,Technologies, Inc. ... will host its,Annual Stockholders Meeting on Thursday, May ... Two Whippany Road, Morristown, New Jersey. The,meeting will ... TECHNOLOGIES, INC., Emisphere Technologies, Inc. is a ...
... -ARIUS report new data and program updates on cancer stem cell ... ... April 15 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... it will be presenting new,findings and program updates related to its ...
Cached Biology Technology:DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR 2Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008 2ARIUS presents new findings for anti-cancer antibody programs at AACR 2ARIUS presents new findings for anti-cancer antibody programs at AACR 3ARIUS presents new findings for anti-cancer antibody programs at AACR 4ARIUS presents new findings for anti-cancer antibody programs at AACR 5
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... A group of 35 researchers from institutions all along ... Science last week to further integrate and refine field measurements ... the U.S. East Coast. An understanding of the behavior ... coastal area, is needed to most accurately predict the rate ...
... , Cambridge, Mass. - January 23, 2012 - New ... form slimy mats on teeth, pipes, surgical instruments, and ... shown that the extracellular matrix (ECM), a mesh of ... creates osmotic pressure that forces biofilms to swell and ...
... CHAMPAIGN, Ill. Land and marine iguanas and ... sites in the Galpagos islands are more likely to ... or protected sites on the islands, researchers report in ... several different sites from free-living reptiles harbored Escherichia ...
Cached Biology News:Researchers meet to refine carbon budget for US East Coast 2Mighty mesh 2Mighty mesh 3Patterns of antibiotic-resistant bacteria found in Galapagos reptiles 2
... 96/384 workstation offers precise 96 and 384-well ... Utilizing 100ul and 200ul disposable tips, the ... accuracy and precision across a volume range ... includes two positions that enable indexing into ...
... reduce the chance of error. Thats the ... using Beckman Coulters extensive experience in laboratory ... the CEQ 8000 is a fully automated ... the capillary array with a patented linear ...
... The AquaMax DW4 liquid handling system from ... washing all in one instrument. The system ... dispensing and plate washing96-, 384- and 1536-welland ... washing. AquaMax DW4 has been optimized to ...
... to identify over 150 peptide modifications ... isoforms, protein subsets, and suppress false ... associations and relationships easily. The software ... relative protein expression analysis for discovery ...
Biology Products: